ChemoCentryx, Inc. (CCXI)
Pre-Market:
| Previous Close | 27.51 |
| Open | 27.77 |
| Bid | 25.00 x 2900 |
| Ask | 28.00 x 800 |
| Day's Range | 25.14 - 27.79 |
| 52 Week Range | 12.71 - 42.16 |
| Volume | |
| Avg. Volume | 1,470,450 |
| Market Cap | 1.862B |
| Beta (5Y Monthly) | 1.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company’s highly potent, orally administered PD-L1 checkpoint
- GlobeNewswire
ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences
SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis and potential application in C3 glomerulopathy, as well as the immuno-oncology potential of CCX559, an orally administered small molecule PD-L1 inhibitor.
- GlobeNewswire
ChemoCentryx Announces Changes to its Board of Directors
-- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to Retire from Board -- SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced changes to the composition of its Board of Directors. David E. Wheadon, M.D., has been elected to the Board as an independent director, and Henry A. McKinnell, Jr., Ph.D., is retiring from the Board, effective May 26, 2022. “Dr. David E. Wheadon adds strength and d
